The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes
The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes
复制标题
DOI：
10.2337/diacare.27.8.1915
复制
发表时间：
2004-08-01
期刊：
影响因子：
16.2
通讯作者：
Astrup, A
中科院分区：
文献类型：
--
作者：
Harder, H;Nielsen, L;Astrup, A
目的-胰高血糖素样肽（GLP）-1是一种肠道激素，发挥肠促胰岛素的作用，抑制人类的食物摄入，但其治疗用途是有限的，由于其半衰期短。这是一项随机、双盲、平行组、安慰剂对照试验，旨在研究长期使用GLP-1衍生物利拉鲁肽（NN 2211）对肥胖2型糖尿病受试者的血糖控制、体重、身体成分和24小时能量消耗的影响。年龄60.0 ± 9.5岁（平均值+/- SD）、HbA（1c）7.5 ± 1.2%和BMI 36.6 ± 4.1 kg/m2的受试者随机接受利拉鲁肽（n = 21）或安慰剂（n = 12）每日单次皮下给药，持续8周。除了体重和血糖参数外，还通过双能X射线吸收测定法（DEXA）扫描和呼吸室中的24小时能量消耗评估身体组成。（利拉鲁肽，-1.90 mmol/l，安慰剂，0.27 mmol/l; P = 0.002）和HbA（1c）（利拉鲁肽，-0.33%，安慰剂，0.47%; P = 0.028）与安慰剂相比。未检测到体重变化（利拉鲁肽，-1.7 kg，安慰剂，-0.9 kg; P = 0.756）。总脂肪量呈非显著性下降趋势（利拉鲁肽，-0.98%，安慰剂，-0.12%，P = 0.088）和瘦体重增加（利拉鲁肽，1.02%，安慰剂，0.23%; P = 0.799）。结论-8周的0.6-与安慰剂组受试者相比，mg利拉鲁肽治疗显著改善了2型糖尿病受试者的血糖控制，且未增加体重。未检测到对24小时能量消耗的影响。
OBJECTIVE- Glucagon-like peptide (GLP)-1 is a gut hormone that exerts incretin effects and suppresses food intake in humans, but its therapeutic use is limited due to its short half-life. This was a randomized, double-blind, parallel-group, placebo-controlled trial investigating the effect of the long-standing GLP-1 derivative liraglutide (NN2211) on glycemic control, body weight, body composition, and 24-h energy expenditure in obese subjects with type 2 diabetes.RESEARCH DESIGN AND METHODS- Thirty-three patients (mean +/- SD) aged 60.0 +/- 9.5 years, with HbA(1c) 7.5 +/- 1.2% and BMI 36.6 +/- 4.1 kg/m(2), were randomized to treatment with a single daily subcutaneous dose of 0.6 mg liraglutide (n = 21) or placebo (n = 12) for 8 weeks. In addition to weight and glycemic parameters, body composition was assessed by dual-energy X-ray absorptiometry (DEXA) scanning and 24-h energy expenditure in a respiratory chamber.RESULTS- After 8 weeks, liraglutide reduced fasting serum glucose (liraglutide, -1.90 mmol/l, and placebo, 0.27 mmol/l; P = 0.002) and HbA(1c) (liraglutide, -0.33%, and placebo, 0.47%; P = 0.028) compared with placebo. No change in body weight was detected (liraglutide, -1.7 kg, and placebo, -0.9 kg; P = 0.756). There was a nonsignificant trend toward a decrease in total fat mass (liraglutide, -0.98%, and placebo, -0.12%; P = 0.088) and toward an increase in lean body mass (liraglutide, 1.02%, and placebo, 0.23%; P = 0.799).CONCLUSIONS- Eight weeks of 0.6-mg liraglutide treatment significantly improved glycemic control without increasing weight in subjects with type 2 diabetes compared with those on placebo. No influence on 24-h energy expenditure was detected.